Past, present, and future perspectives of ultrasound-guided ablation of liver tumors: Where could artificial intelligence lead interventional oncology?

doi:10.35713/aic.v5.i1.96690

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (364)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-8) series.

Item

Count

PDF

HTML

230

Figures (1-8)

Sum=243

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=85

Publishing Process of This Article

Item

Count

Browse

Download

Sum=31

Jul 18, 2024 (publication date) through Jul 22, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

Artificial Intelligence in Cancer

ISSN

2644-3228

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

Artif Intell Cancer. Jul 18, 2024; 5(1): 96690
Published online Jul 18, 2024. doi: 10.35713/aic.v5.i1.96690

Past, present, and future perspectives of ultrasound-guided ablation of liver tumors: Where could artificial intelligence lead interventional oncology?

Paola Tombesi, Andrea Cutini, Valentina Grasso, Francesca Di Vece, Ugo Politti, Eleonora Capatti, Florence Labb, Stefano Petaccia, Sergio Sartori

Paola Tombesi, Andrea Cutini, Valentina Grasso, Francesca Di Vece, Ugo Politti, Eleonora Capatti, Sergio Sartori, Department of Internal Medicine, Section of Interventional Ultrasound, St. Anna Hospital, Ferrara 44100, Italy

Florence Labb, Stefano Petaccia, Esaote S.p.A., Genova 16100, Italy

Co-first authors: Paola Tombesi and Sergio Sartori.

Author contributions: Tombesi P, Cutini A, Grasso V, Di Vece F, Politti U, Capatti E, Labb F, Petaccia S, and Sartori S equally contributed to conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

Conflict-of-interest statement: All authors declare no conflicts of interest related to this publication.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Sergio Sartori, MD, Adjunct Professor, Chief Doctor, Department of Internal Medicine, Section of Interventional Ultrasound, St. Anna Hospital, Via A. Moro 8, Ferrara 44100, Italy. srs@unife.it

Received: May 14, 2024
Revised: June 26, 2024
Accepted: July 10, 2024
Published online: July 18, 2024
Processing time: 63 Days and 23.9 Hours

Core Tip

Core Tip: Starting from the first experiences with ethanol injection, constant technical improvements in both thermal ablation and ultrasound imaging have led clinicians in interventional oncology to break the so-called 3-cm barrier in the percutaneous treatment of primary and secondary liver tumors. At present, advanced software powered by artificial intelligence has been developed to precisely target tumor margins and/or residual viable tumor tissue, opening the way to the percutaneous ablation of tumors up to 5-7 cm in size.